Fasudil mesilate | 1001206-62-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: Fasudil mesilate
• 英文别名: 5-(1,4-diazepan-1-ylsulfonyl)isoquinoline;methanesulfonic acid
• CAS: 1001206-62-7
• 化学式: C15H21N3O5S2
• 分子量: 387.5
• InChiKey: MVCDPGYHRHUECK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.72
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  133
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Controlled release dosage form
  申请人：TRIASTEK, INC.

  公开号：US10143626B2

  公开（公告）日：2018-12-04

  The present invention generally relates to a pharmaceutical dosage form and controlled release of biologically active agents, diagnostic agents, reagents, cosmetic agents, and agricultural/insecticide agents. In one embodiment, the dosage form has a substrate that forms a compartment, wherein the substrate includes at least a first piece and a second piece, wherein the first piece operably links to the second piece. The dosage form contains a drug content that is loaded into the compartment. The dosage form also has a releaser operably linked to the substrate which upon contact with water or body fluid is capable of separating the first and second piece to open the compartment and release the drug content.

  本发明一般涉及一种药物剂型和生物活性制剂、诊断制剂、试剂、化妆品制剂和农用/杀虫剂制剂的控制释放。在一个实施方案中，该剂型具有形成隔室的基质，其中基质至少包括第一片和第二片，其中第一片与第二片可操作地连接。剂型含有装入隔室的药物成分。该剂型还具有与基质可操作连接的释放器，该释放器在与水或体液接触时能够分离第一和第二片，从而打开隔室并释放药物成分。
• Oral drug dosage forms having desired drug release profiles and uses thereof
  申请人：Triastek, Inc.

  公开号：US10258575B2

  公开（公告）日：2019-04-16

  The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.

  本公开提供了一种用于口服的稳定固体药物剂型。该剂型包括至少形成一个小室的基质和装入小室的药物成分。该剂型的设计使药物内容物中的活性药物成分以可控方式释放。
• Compartmented pharmaceutical dosage forms
  申请人：Triastek, Inc.

  公开号：US10363220B2

  公开（公告）日：2019-07-30

  The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.

  本公开提供了一种用于口服的稳定固体药物剂型。该剂型包括至少形成一个小室的基质和装入小室的药物成分。该剂型的设计使药物内容物中的活性药物成分以可控方式释放。
• Oral drug dosage form comprising drug in the form of nanoparticles
  申请人：Triastek, Inc.

  公开号：US10973767B2

  公开（公告）日：2021-04-13

  The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.

  本公开提供了一种用于口服的稳定固体药物剂型。该剂型包括至少形成一个小室的基质和装入小室的药物成分。该剂型的设计使药物内容物中的活性药物成分以可控方式释放。
• DOSAGE FORMS AND USE THEREOF
  申请人：Triastek, Inc.

  公开号：EP3302442A1

  公开（公告）日：2018-04-11